ST elevation myocardial infarction anticoagulant and antithrombotic therapy: Difference between revisions
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
Management of the patient with ST elevation myocardial infarction requires inhibition of both the the generation of thrombin (the [[coagulation cascade]]) (via antithrombins) as well as the [[platelet]] (via antiplatelet agents). Selection of the appropriate antithrombin depends upon a variety of factors including the choice of revascularization strategy. This chapter reviews data supporting the use of both parenteral antithrombotic and oral antithrombotic (anticoagulant) agents. | |||
==Sites of Action of Antithrombins== | ==Sites of Action of Antithrombins== | ||
Revision as of 00:00, 22 April 2009
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Management of the patient with ST elevation myocardial infarction requires inhibition of both the the generation of thrombin (the coagulation cascade) (via antithrombins) as well as the platelet (via antiplatelet agents). Selection of the appropriate antithrombin depends upon a variety of factors including the choice of revascularization strategy. This chapter reviews data supporting the use of both parenteral antithrombotic and oral antithrombotic (anticoagulant) agents.
Sites of Action of Antithrombins
The majority of established and investigational antithrombins [1] target two factors in the coagulation cascade: Factor Xa and Factor II.
Parenteral Drugs Targeting Factor Xa
Idraparinux
Oral Drugs Targeting Factor Xa
Rivaroxaban
Apixaban
LY517717
YM150
DU-176b
PRT-054021
References
- ↑ Weitz JI (2006). "Emerging anticoagulants for the treatment of venous thromboembolism". Thromb. Haemost. 96 (3): 274–84. doi:10.1160/TH06-05-0234. PMID 16953267. Unknown parameter
|month=ignored (help)